impacting rare diseases healthcare by case based telelearning description of the dutch pilot metabolic diseases echo

Original title: “Impacting Rare Diseases Healthcare by Case-Based Telelearning: Description of the Dutch Pilot Metabolic Diseases ECHO.”

The new partnership follows Roche’s recent R&D expansion in Boston focused on development for cardiovascular, renal and metabolic diseases.

Original title: “Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs”

age and sex specific distribution of the triglyceride glucose index in a large chinese population cross sectional study

Original title: “Age- and Sex-Specific Distribution of the Triglyceride-Glucose Index in a Large Chinese Population: Cross-Sectional Study.”

correction current status of public education on endocrine and metabolic diseases carried out by academic journals wechat official accounts a retrospective study

Original title: “Correction: Current status of public education on endocrine and metabolic diseases carried out by academic journals' WeChat official accounts: a retrospective study.”

tirzepatide in metabolic diseases clinical efficacy and safety beyond diabetes and obesity

Original title: “Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity.”

Shift Toward One Time Curative ... symptomatic treatments. Industry Developments Expansion of Clinical Stage Gene Therapy Pipelines: Multiple therapies targeting neuromuscular, metabolic, and hematologic rare diseases are progressing through trials.... Shift Toward One Time Curative Treatments: Gene therapy offers long term or permanent therapeutic benefit compared with chronic symptomatic treatments. Industry Developments Expansion of Clinical Stage Gene Therapy Pipelines: Multiple therapies targeting neuromuscular, metabolic, and hematologic rare diseases are progressing through trials. Press release - DataM intelligence 4 Market Research LLP - Gene Therapy for Rare Disease Market to Reach US$ 24.54 Billion by 2033 at 26.5% CAGR; North America Leads with 45% Share - Key Players: Novartis AG, Sarepta Therapeutics, Inc., bluebird bio, Inc. - published on openPR.com Asia Pacific - Holds 18% share: Expanding biotech innovation, government funding, and increasing clinical trial activity accelerate adoption. Latin America - Holds 4% share: Gradual improvement in rare disease diagnosis and access to advanced therapies supports emerging demand. The Gene Therapy for Rare Disease Market was valued at USD 3 01 billion in 2024 and is projected to reach USD 24 54 billion by 2033 expanding at a CAGR of 26 5 during the forecast period from 2025 ...

Original title: “Gene Therapy for Rare Disease Market to Reach US$ 24.54 Billion by 2033 at 26.5% CAGR; North America Leads with 45% Share - Key Players: Novartis AG, Sarepta Therapeutics, Inc., bluebird bio, Inc.”